The Actemra Drug Market is driven by increasing prevalence of rheumatoid arthritis

The Actemra drug market comprises biologic disease-modifying antirheumatic drugs (DMARDs) that treat rheumatoid arthritis by inhibiting interleukin-6 (IL-6) receptor activity. Actemra is also used for slowing the progression of joint damage and improving physical function in people with moderately to severely active rheumatoid arthritis. 

These Actemra Drug Market are administered via intravenous or subcutaneous injections and are highly effective in reducing inflammation and slowing the progression of joint damage.

The Actemra drug market is estimated to be valued at USD 3.796 Bn in 2024 and is expected to reach USD 6.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.

Key players operating in the Actemra drug market are Roche, Pfizer, Johnson & Johnson, Novartis, and AbbVie. These companies offer a wide range of monoclonal antibodies and biologics that selectively target specific cells or proteins involved in the immune response.

The increasing incidence of rheumatoid arthritis due to sedentary lifestyles and aging populations is a major factor driving the demand for Actemra drugs globally. Furthermore, the rising health awareness and growing adoption of biologics over conventional DMARDs are also stimulating market growth.

The growing geriatric population succumbing to rheumatoid arthritis is further bolstering the Actemra drug market. As per estimates, over 50 million people suffer from rheumatoid arthritis worldwide, and more than 1.3 million Americans are affected by the condition. The symptoms often worsen with age and incapacitate mobility and independence in old people. Thus, the rapidly expanding aging demographics, especially in developed nations, present lucrative opportunities for Actemra drug manufacturers.

The global expansion of key market players through new product launches and strategic collaborations is also propelling the Actemra drug industry. For instance, Roche has strengthened its market presence across Asia Pacific and Europe by receiving regulatory approvals to commercialize its Actemra biosimilars. Similarly, prominent generics manufacturers have further augmented the market accessibility and affordability of such drugs through their cost-effective biosimilar offerings.

Personalized medicines trend is a key trend being witnessed in the Actemra drug market. Growing focus of pharmaceutical companies towards precision medicine is accelerating R&D for developing biomarkers to identify responders and non-responders for biologic drugs like Actemra. This helps in administering the right treatment to the right patient and optimize outcomes.

Porter's Analysis
Threat of new entrants: High costs of regulatory approvals and brand building pose barriers for new players.
Bargaining power of buyers: Large pharmaceutical companies have higher bargaining power over pricing for bulk supply.
Bargaining power of suppliers: Suppliers of active pharmaceutical ingredients have bargaining power over prices due to limited alternatives.
Threat of new substitutes: Substitute drugs pose a threat, however Actemra caters to less common ailments limiting threat of substitutes in short term.
Competitive rivalry: Intense competition exists among players to capture more market share through innovative delivery systems and promotional campaigns.

The geographical region where the value of Actemra drug market is concentrated is North America. The United States contributes to more than half of global Actemra sales owing to rising cases of rheumatoid arthritis. The accessibility of healthcare facilities and growing acceptance of biologics in treatment also drive the North American market.

Asia Pacific region is expected to witness the fastest growth in the Actemra drug market during the forecast period. This is attributed to increasing healthcare expenditure, large patient pool suffering from arthritis, and expanding pharmaceutical industry in emerging economies like China and India. Favorable regulatory environment promoting usage of biologics further supports market growth across Asia Pacific.

Get this Report in Japanese Language: アズテムラ その他の市場

Get this Report in Korean Language:  아즈템라 기타 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)